This is a useful overview of CAR (chimeric antigen receptor) T-cell therapy and its application to GBM published a few days ago at CancerCommons, written by their chief scientist.
Reengineering Immune System Cells to Fight Glioblastoma (click on link)
Showing posts with label T-cell_therapies. Show all posts
Showing posts with label T-cell_therapies. Show all posts
Sunday, 13 August 2017
Thursday, 1 June 2017
Car T cells
Dear all,
Does anyone know of any place ( in the world!) that is doing car t cells on a compassionate basis? My son is under 18 still, so it doesnt seem possible for him to get anything at the City of Hope trial. Thanks!
Does anyone know of any place ( in the world!) that is doing car t cells on a compassionate basis? My son is under 18 still, so it doesnt seem possible for him to get anything at the City of Hope trial. Thanks!
Tuesday, 25 April 2017
Navigating the Brain Tumor Maze with Professor Rajiv Khanna
This will be particularly interesting for patients in Australia and much of the discussion is about CMV-directed T-cell therapy being developed there in Brisbane. The discussion turns to GBM at minute 25:25 of the podcast. Click here for the link.
Tuesday, 7 June 2016
New trial at MD Anderson (Houston) for newly diagnosed or first recurrent GBM
A Phase I/II Clinical Trial of Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients (click here to view detailed trial description)
This is a phase 2, non-randomized, open-label trial.
There are 3 arms: first, a dose expansion study to find the maximum tolerated dose of the CMV-specific T-cells in recurrent GBM at first relapse, along with dose-dense temozolomide.
After finding the maximum tolerated dose, the second arm of recurrent GBM patients undergoes temozolomide treatment for 21 days followed by the first administration of CMV-specific T-cells, followed by surgery for the recurrent tumor on day 30. After surgery patients undergo another 3 cycles of dose-dense temzolomide followed by T-cell infusions. Temozolomide is continued for a maximum of 12 cycles or until disease progression.
The third arm consists of newly diagnosed GBM patients treated with dose-dense temozolomide and CMV-specific T-cells, after conventional radiochemotherapy.
All patients undergo a leukapheresis procedure to obtain T-cells, which are reinjected after conditioning.
This is a phase 2, non-randomized, open-label trial.
There are 3 arms: first, a dose expansion study to find the maximum tolerated dose of the CMV-specific T-cells in recurrent GBM at first relapse, along with dose-dense temozolomide.
After finding the maximum tolerated dose, the second arm of recurrent GBM patients undergoes temozolomide treatment for 21 days followed by the first administration of CMV-specific T-cells, followed by surgery for the recurrent tumor on day 30. After surgery patients undergo another 3 cycles of dose-dense temzolomide followed by T-cell infusions. Temozolomide is continued for a maximum of 12 cycles or until disease progression.
The third arm consists of newly diagnosed GBM patients treated with dose-dense temozolomide and CMV-specific T-cells, after conventional radiochemotherapy.
All patients undergo a leukapheresis procedure to obtain T-cells, which are reinjected after conditioning.
Monday, 28 December 2015
CAR T-CELL THERAPY TO FIGHT TUMORS
Very interesting and I agree is a potentially productive treatment against GBM.
http://www.cityofhope.org/brain-cancer-2016-using-car-t-cell-therapy-to-fight-tumors
http://www.cityofhope.org/brain-cancer-2016-using-car-t-cell-therapy-to-fight-tumors
Subscribe to:
Posts (Atom)